Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Closed, never started.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| autologous followed by nonmyeloablative allogeneic transplant | Procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis. |
| Measure | Description | Time Frame |
|---|---|---|
| Toxicity of therapy | ||
| Changes in marrow and serum abnormalities | ||
| Improvement in end-organ function. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Keith Stockerl-Goldstein, MD | Stanford University | Principal Investigator |
Not provided
| ID | Term |
|---|---|
| D000686 | Amyloidosis |
| ID | Term |
|---|---|
| D057165 | Proteostasis Deficiencies |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided